Longitudinal evaluation of criteria for subjective cognitive decline and preclinical Alzheimer's disease in a memory clinic sample

Marie Eckerström¹, Mattias Göthlin¹, Sindre Rolstad¹, Erik Hessen², Carl Eckerström¹, Arto Nordlund¹, Boo Johansson³, Johan Svensson⁴, Michael Jonsson¹, Simona Sacuiu¹, Anders Wallin¹

Affiliations

¹ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
² Department of Neurology, Akershus University Hospital, Oslo, Norway.
³ Department of Psychology, University of Gothenburg, Gothenburg, Sweden.
⁴ Department of Internal Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

PMID:28560310
PMCID: PMC5443895
DOI: 10.1016/j.dadm.2017.04.006

Longitudinal evaluation of criteria for subjective cognitive decline and preclinical Alzheimer's disease in a memory clinic sample

Marie Eckerström et al. Alzheimers Dement (Amst).2017.

.2017 May 16:8:96-107.

doi: 10.1016/j.dadm.2017.04.006. eCollection 2017.

Authors

Marie Eckerström¹, Mattias Göthlin¹, Sindre Rolstad¹, Erik Hessen², Carl Eckerström¹, Arto Nordlund¹, Boo Johansson³, Johan Svensson⁴, Michael Jonsson¹, Simona Sacuiu¹, Anders Wallin¹

Affiliations

¹ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
² Department of Neurology, Akershus University Hospital, Oslo, Norway.
³ Department of Psychology, University of Gothenburg, Gothenburg, Sweden.
⁴ Department of Internal Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

PMID:28560310
PMCID: PMC5443895
DOI: 10.1016/j.dadm.2017.04.006

Abstract

Introduction: Subjective cognitive decline (SCD) and biomarker-based "at-risk" concepts such as "preclinical" Alzheimer's disease (AD) have been developed to predict AD dementia before objective cognitive impairment is detectable. We longitudinally evaluated cognitive outcome when using these classifications.

Methods: Memory clinic patients (n = 235) were classified as SCD (n = 122): subtle cognitive decline (n = 36) and mild cognitive impairment (n = 77) and subsequently subclassified into SCDplus and National Institute on Aging-Alzheimer's Association (NIA-AA) stages 0 to 3. Mean (standard deviation) follow-up time was 48 (35) months. Proportion declining cognitively and prognostic accuracy for cognitive decline was calculated for all classifications.

Results: Among SCDplus patients, 43% to 48% declined cognitively. Among NIA-AA stage 1 to 3 patients, 50% to 100% declined cognitively. The highest positive likelihood ratios (+LRs) for subsequent cognitive decline (+LR 6.3), dementia (+LR 3.4), and AD dementia (+LR 6.5) were found for NIA-AA stage 2.

Discussion: In a memory clinic setting, NIA-AA stage 2 seems to be the most successful classification in predicting objective cognitive decline, dementia, and AD dementia.

Keywords: Alzheimer's disease; Classification; Clinical progression; Dementia; Diagnosis; Memory clinic; Mild cognitive impairment; Neuropsychology; Prediction.

PubMed Disclaimer

Figures

**Fig. 1**
Operationalization of SCD and NIA-AA stage subclassifications.

**Fig. 2**
Cognitive outcome at follow-up for the subclassification groups. Abbreviations: MCI, mild cognitive impairment; NIA-AA, National Institute on Aging–Alzheimer's Association; SCD, subjective cognitive decline.

See this image and copyright information in PMC

References

1. Morris J.C. Mild cognitive impairment and preclinical Alzheimer's disease. Geriatrics. 2005;Suppl:9–14. - PubMed
1. Jack C.R., Jr., Albert M.S., Knopman D.S., McKhann G.M., Sperling R.A., Carrillo M.C. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:257–262. - PMC - PubMed
1. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280–292. - PMC - PubMed
1. Drachman D.A. The amyloid hypothesis, time to move on: amyloid is the downstream result, not cause, of Alzheimer's disease. Alzheimers Dement. 2014;10:372–380. - PubMed
1. Hessen E., Nordlund A., Stalhammar J., Eckerstrom M., Bjerke M., Eckerstrom C. T-Tau is associated with objective memory decline over two years in persons seeking help for subjective cognitive decline: a report from the Gothenburg-Oslo MCI Study. J Alzheimers Dis. 2015;47:619–628. - PubMed

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Molecular Biology Databases
- NIAID Data Ecosystem - Find datasets on Infectious and Immune-mediated Diseases

Movatterモバイル変換

Account

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Full text links

Actions

Longitudinal evaluation of criteria for subjective cognitive decline and preclinical Alzheimer's disease in a memory clinic sample

Affiliations

Longitudinal evaluation of criteria for subjective cognitive decline and preclinical Alzheimer's disease in a memory clinic sample

Authors

Affiliations

Abstract

Figures

References

LinkOut - more resources

Full Text Sources

Other Literature Sources

Molecular Biology Databases